Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin

被引：0

作者：

Thitima Kongnakorn

Tereza Lanitis

Lieven Annemans

Vincent Thijs

Marnix Goethals

Sophie Marbaix

Jean-Claude Wautrecht

机构：

[1] Evidera,Department of Neurology

[2] Ghent University (Ugent),Department of Vascular Diseases

[3] Brussels University (VUB),undefined

[4] University Hospital Leuven,undefined

[5] Mariaziekenhuis Noord-Limburg,undefined

[6] Pfizer NV/SA,undefined

[7] Hôpital Erasme - ULB,undefined

[8] Université Libre de Bruxelles,undefined

来源：

Clinical Drug Investigation | 2015年 / 35卷

关键词：

Warfarin; Dabigatran; Rivaroxaban; Apixaban; Efficiency Frontier;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：109 / 119

页数：10

共 50 条

[41] Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan
Chang, Chia-Hsien
Yang, Yea-Huei Kao
Chen, Jyh-Hong
Lin, Li-Jen
[J]. THROMBOSIS RESEARCH, 2014, 133 (05) : 782 - 789
[42] Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada Comparative efficacy and cost-effectiveness
Kansal, Anuraag R.
Sharma, Michael
Bradley-Kennedy, Carole
Clemens, Andreas
Monz, Brigitta U.
Peng, Siyang
Roskell, Neil
Sorensen, Sonja V.
[J]. THROMBOSIS AND HAEMOSTASIS, 2012, 108 (04) : 672 - 682
[43] New Anticoagulants for Prevention of Stroke in Patients with Atrial Fibrillation
Viles-Gonzalez, Juan F.
Fuster, Valentin
Halperin, Jonathan L.
[J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2011, 22 (08) : 948 - 955
[44] Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
Senoo, Keitaro
Lane, Deirdre A.
Lip, Gregory Y. H.
[J]. CURRENT PROBLEMS IN CARDIOLOGY, 2014, 39 (09) : 319 - 344
[45] NEW ORAL ANTICOAGULANTS VERSUS WARFARIN ON PRIMARY AND SECONDARY PREVENTION OF STROKE IN PATIENTS WITH ATRIAL FIBRILLATION: A META-ANALYSIS
Gomez-Outes, A.
Terleira-Fernandez, A.
Suarez-Gea, M. L.
Vargas-Castrillon, E.
[J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2012, 111 : 32 - 32
[46] NEW ORAL ANTICOAGULANTS VERSUS WARFARIN FOR STROKE PREVENTION IN ATRIAL FIBRILLATION: DEVELOPMENT OF COVERAGE DECISION FRAMEWORKS
Lee, K. M.
Shukla, V
Oxman, A. D.
Wells, G.
[J]. VALUE IN HEALTH, 2013, 16 (03) : A296 - A296
[47] Effectiveness and Safety of Apixaban and Rivaroxaban Versus Warfarin for the Secondary Prevention of Stroke or Systemic Embolism Among Nonvalvular Atrial Fibrillation Patients
Coleman, Craig
Bunz, Thomas
[J]. NEUROLOGY, 2017, 88
[48] EFFECTIVENESS AND SAFETY OF APIXABAN AND RIVAROXABAN VERSUS WARFARIN FOR THE SECONDARY PREVENTION OF STROKE OR SYSTEMIC EMBOLISM AMONG NONVALVULAR ATRIAL FIBRILLATION PATIENTS
Coleman, Craig I.
Bunz, Thomas J.
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 458 - 458
[49] COMPARATIVE EFFECTIVENESS OF EDOXABAN AND WARFARIN IN PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN NON-VALVULAR ATRIAL FIBRILLATION USING OBSERVATIONAL HEALTHCARE DATA
Zhou, L.
Zhang, R.
Chakraborty, P.
Farooq, F.
Alford, Hensley S.
[J]. VALUE IN HEALTH, 2018, 21 : S56 - S56
[50] COST-EFFECTIVENESS OF NOVEL ORAL ANTICOAGULANTS FOR STROKE PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN CHINA
Guo, W.
Tian, X.
Li, W.
Han, S.
[J]. VALUE IN HEALTH, 2018, 21 : S30 - S30

← 1 2 3 4 5 →